関節リウマチ：世界医薬品市場予測及び市場分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 13
1.2 List of Figures 18
2 Introduction 20
2.1 Catalyst 20
2.2 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and Pathophysiology 22
3.1.1 Etiology 22
3.1.2 Pathophysiology 22
3.1.3 Prognosis 25
3.1.4 Quality of Life 25
3.2 Symptoms 26
4 Epidemiology 27
4.1 Risk Factors and Co-morbidities 27
4.1.1 Smoking is the only established lifestyle risk factor for RA 27
4.1.2 Genetics account for as much as 60% of RA cases 28
4.1.3 Half of RA deaths are attributed to cardiac-related conditions 28
4.2 Global Trends 28
4.3 Forecast Methodology 28
4.3.1 Sources used 29
4.3.2 Forecast assumptions and methods 30
4.4 Epidemiological Forecast 31
5 Disease Management 32
5.1 Treatment Overview 35
5.2 US 38
5.2.1 Diagnosis 38
5.2.2 Clinical Practice 38
5.3 France 40
5.3.1 Diagnosis 40
5.3.2 Clinical Practice 40
5.4 Germany 41
5.4.1 Diagnosis 41
5.4.2 Clinical Practice 41
5.5 Italy 42
5.5.1 Diagnosis 42
5.5.2 Clinical Practice 42
5.6 Spain 43
5.6.1 Diagnosis 43
5.6.2 Clinical Practice 43
5.7 UK 44
5.7.1 Diagnosis 44
5.7.2 Clinical Practice 44
5.8 Japan 46
5.8.1 Diagnosis 46
5.8.2 Clinical Practice 46
5.9 Australia 47
5.9.1 Diagnosis 47
5.9.2 Clinical Practice 47
5.10 China 48
5.10.1 Diagnosis 48
5.10.2 Clinical Practice 48
5.11 India 49
5.11.1 Diagnosis 49
5.11.2 Clinical Practice 49
6 Competitive Assessment 50
6.1 Overview 50
6.2 Strategic Competitor Assessment 50
6.3 Product Profiles – Major Brands 52
6.3.1 Enbrel (etanercept) 52
6.3.2 Humira (adalimumab) 58
6.3.3 Remicade (infliximab) 62
6.3.4 Simponi (golimumab) 67
6.3.5 Cimzia (certolizumab pegol) 72
6.3.6 Orencia (abatacept) 77
6.3.7 Actemra/RoActemra (tocilizumab) 82
6.3.8 Rituxan/MabThera (rituximab) 87
6.3.9 Methotrexate Sodium (numerous generic names) 91
6.3.10 DMARDs 95
7 Opportunity and Unmet Need 96
7.1 Overview 96
7.2 Unmet Needs 97
7.2.1 More rheumatologists in the field and physician knowledge of the disease 97
7.2.2 More cost-effective therapies through oral formulation and biosimilars 97
7.2.3 The development of predictive tests and discovery of biomarkers 97
7.2.4 The discovery of curative therapies 98
7.2.5 Improved drug safety and efficacy profiles 98
7.3 Gap Analysis 99
7.4 Opportunities 100
7.4.1 Predictive tools for diagnosis and treatment 100
7.4.2 Target specificity 100
8 Pipeline Assessment 101
8.1 Overview 101
8.2 Clinical Trial Mapping 102
8.2.1 Clinical Trials by Country 102
8.3 Clinical Trials by Phase and Trial Status 103
8.4 Promising Drugs in Clinical Development 105
8.4.1 Tofacitinib (CP-690550) 107
8.4.2 Fostamatinib (previously R788) 115
8.4.3 RAVAX 120
8.4.4 Secukinumab (AIN457) 124
8.4.5 Masitinib (AB101) 129
8.4.6 Baricitinib (formerly LY3009104/INCB28050) 134
8.4.7 Careram/KOLBET (iguratimod/T-614) 139
8.4.8 Sarilumab (REGN88/SAR153191) 142
8.4.9 Sirukumab (CNTO 136) 146
9 Current and Future Players 150
9.1 Overview 150
9.2 Trends in Corporate Strategy 152
9.3 Company Profiles 153
9.3.1 Abbott 153
9.3.2 Pfizer 155
9.3.3 Amgen 157
9.3.4 Johnson & Johnson 159
9.3.5 Eli Lilly 161
9.3.6 Bristol-Myers Squibb (BMS) 162
9.3.7 UCB 163
9.3.8 Roche 165
9.3.9 GlaxoSmithKline 167
10 Market Outlook 169
10.1 Global Markets 169
10.1.1 Forecast 169
10.1.2 Drivers and Barriers – Global Issues 172
10.2 United States 174
10.2.1 Forecast 174
10.2.2 Key Events 176
10.2.3 Drivers and Barriers 177
10.3 France 179
10.3.1 Forecast 179
10.3.2 Key Events 182
10.3.3 Drivers and Barriers 183
10.4 Germany 185
10.4.1 Forecast 185
10.4.2 Key Events 187
10.4.3 Drivers and Barriers 188
10.5 Italy 190
10.5.1 Forecast 190
10.5.2 Key Events 192
10.5.3 Drivers and Barriers 193
10.6 Spain 194
10.6.1 Forecast 194
10.6.2 Key Events 196
10.6.3 Drivers and Barriers 197
10.7 United Kingdom 198
10.7.1 Forecast 198
10.7.2 Key Events 200
10.7.3 Drivers and Barriers 201
10.8 Japan 203
10.8.1 Forecast 203
10.8.2 Key Events 206
10.8.3 Drivers and Barriers 206
10.9 Australia 209
10.9.1 Forecast 209
10.9.2 Key Events 211
10.9.3 Drivers and Barriers 212
10.10 China 213
10.10.1 Forecast 213
10.10.2 Key Events 215
10.10.3 Drivers and Barriers 215
10.11 India 217
10.11.1 Forecast 217
10.11.2 Key Events 219
10.11.3 Drivers and Barriers 220
11 Appendix 222
11.1 Abbreviations 222
11.2 Bibliography 225
11.3 Methodology 240
11.4 Forecasting Methodology 240
11.4.1 Diagnosed Rheumatoid Arthritis Patients 240
11.4.2 Percent Drug-treated Patients 241
11.4.3 Drugs Included in Each Therapeutic Class 241
11.4.4 Launch and Patent Expiry Dates 242
11.4.5 General Pricing Assumptions 243
11.4.6 Individual Drug Assumptions 244
11.4.7 Generic Erosion 250
11.4.8 Pricing of Pipeline agents 250
11.5 Physicians and Specialists Included in this Study 251
11.6 Primary Research – Prescriber Survey 252
11.7 About the Authors 253
11.7.1 Analysts 253
11.7.2 Global Head of Healthcare 254
11.8 About GlobalData 255
11.9 Contact Us 255
11.10 Disclaimer 255